Background: Androgen deprivation therapy (ADT) in men with prostate cancer is associated with bone loss and fractures VSports手机版. .

Objective: To determine whether once-weekly oral bisphosphonate can prevent bone loss and reduce bone turnover in men receiving ADT V体育安卓版. .

Design: Randomized, double-blind, placebo-controlled, partial crossover trial. First-year, preplanned analysis of a 2-group, parallel-design phase V体育ios版. .

Setting: University medical center VSports最新版本. .

Patients: 112 men with nonmetastatic prostate cancer receiving ADT V体育平台登录. .

Intervention: Alendronate, 70 mg once weekly, or placebo VSports注册入口. All patients received calcium and vitamin D supplementation. .

Measurements: Bone mineral density of the spine and hip and markers of bone resorption and formation V体育官网入口. .

Results: At baseline, 39% of men had osteoporosis and 52% had low bone mass. In men treated with alendronate, bone mineral density increased over 1 year by 3. 7% (95% CI, 2. 8% to 4. 6%; P < 0. 001) at the spine and 1. 6% (CI, 0. 4% to 2. 8%; P = 0. 008) at the femoral neck. Men in the placebo group had losses of 1. 4% (CI, -2. 7% to - 0 VSports在线直播. 03%; P = 0. 045) at the spine and 0. 7% (CI, -1. 5% to 0. 01%; P = 0. 081) at the femoral neck. At 12 months, the difference between the 2 groups was 5. 1 percentage points (CI, 3. 5 to 6. 7 percentage points; P < 0. 001) at the spine and was 2. 3 percentage points (CI, 1. 0 to 3. 7 percentage points; P < 0. 001) at the femoral neck. Bone turnover statistically significantly decreased with active therapy compared with placebo. The groups did not differ in adverse events. .

Limitations: The study was short (1 year) and was not powered to detect differences in the frequency of fractures.

Conclusions: Bone loss that occurred with ADT was prevented and improved with once-weekly oral alendronate. Because most men have low bone mass or osteoporosis, physicians should assess their patients' bone density and provide preventive and therapeutic measures as appropriate. ClinicalTrials.gov registration number: NCT00048841.